Select Language
Free Registration
My Cart

Laminin 111 E8

Product Inquiry

Laminin 111 E8 Background

Laminin 111 is an extracellular matrix protein that has also been promoted for its ability to improve muscle regeneration and stabilize the plasma membrane in multiple forms of muscular dystrophy. Laminin 111 E8 is composed of the C-terminal end of Laminin alpha1, beta 1 and gamma 1 chains.

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
KN-057KN-057; KN057Phase 3 ClinicalSuzhou Alphamab Co LtdHemophilia A; Hemophilia B
Details
MG-1113MG-1113Phase 1 ClinicalGC Biopharma CorpHemophilia A
Details
AP-017AP017; AP-017Phase 1 ClinicalAnyuan Pharmaceutical Technology (Shanghai) Co LtdHemophilia A; Hemophilia B
Details

Marketed Drug Information

English NameResearch CodeHighest Development StageCompanyFirst Brand NameFirst Approved CountryFirst IndicationFirst Approved CompanyFirst Approved DateIndicationClinical Trial
ConcizumabmAbTFPI2021; NN-7415; NNC-0172-0000-2021; Anti-TFPI; mAb-2021; NNC-0172-2021; NNC-172-2021ApprovedNovo Nordisk A/SAlhemoCanadaHemophilia BNovo Nordisk Canada Inc2023-04-17Hemophilia A; Hemophilia B; Hemorrhage
Details
MarstacimabPF-6741086; PF-06741086ApprovedPfizer IncHYMPAVZIUnited StatesHemophilia A; Hemophilia BPfizer Inc2024-10-11Hemophilia A; Hemophilia B; Hemorrhage
Details
  • Product Inquiry
  • Marketed Drug Information
  • Clinical Drug Information
Share to:

Join UsLegalSite MapPrivacy PolicyTerms and Conditions
Website Feedback
Contact Us

[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521

order@acrobiosystems.com

[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland